Allergan announced it has completed its acquisition of Zeltiq Aesthetics for $2.4 billion in cash.
Zeltiq’s proprietary controlled-cooling fat-reducing treatment, CoolSculpting, is the sales leader in the cash-pay body contouring segment of medical aesthetics, according to a news release from Allergan.
The CoolSculpting system cools targeted fat cells to induce a controlled elimination of fat cells without affecting surrounding tissue, according to the release.
Zeltiq stockholders approved the transaction during its stockholder meeting April 27, Allergan reported.
The acquisition makes body contouring the third pillar of Allergan’s global aesthetics portfolio, joining its facial aesthetics and plastic surgery and regenerative medicine businesses. The system will be targeted to plastic surgeons, dermatologists and other aesthetic providers, according to the release.
“In my practice, there is a growing demand from patients for less invasive treatments for bothersome pockets of fat on their body,” Grant Stevens, MD, chief medical officer and co-founder of Orange Twist, and clinical professor of plastic surgery at University of Southern California School of Medicine, stated in the release. “I am excited to see the CoolSculpting technology being added to Allergan’s broad aesthetic product offering, and eager to see how they will expand the opportunity for body contouring.”